Welcome to the Starpharma Investor CentreStarpharma Holdings Limited is an Australian stock exchange listed biotechnology company with products based on its dendrimer technology platform. |
 |
Latest News & Announcements
.png)
Appointment of Company Secretary (ASX Announcement)
Feb 1st, 2023
Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) advises, in accordance with ASX Listing Rule 3.16.1, that Ms Tracy Weimar from Vistra Australia has been appointed as interim Company Secretary, effective today.
Read More
Dr Russell Basser appointed as non-executive director (ASX Announcement)
Jan 31st, 2023
The Board of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) is pleased to announce the appointment of Dr Russell Basser as an independent non-executive director, effective from 20 February 2023.
Dr Basser is a medical oncologist and former corporate executive with over 30 years of international medical and biopharmaceutical experience, including 21 years at CSL.
Dr Basser has substantial expertise in international drug and vaccine development, having held multiple senior executive roles whilst at CSL, including Senior Vice President (SVP) of Research and Development at CSL Seqirus; Chief Medical Officer at CSL Limited / CSL Behring; and SVP of Global Clinical Research and Development at CSL Behring / CSL Limited.
Read More
Reports & Presentations
Click here for financial reports archive
Appointment of Company Secretary (ASX Announcement)
Feb 1st, 2023
Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) advises, in accordance with ASX Listing Rule 3.16.1, that Ms Tracy Weimar from Vistra Australia has been appointed as interim Company Secretary, effective today.
Read More
Dr Russell Basser appointed as non-executive director (ASX Announcement)
Jan 31st, 2023
The Board of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) is pleased to announce the appointment of Dr Russell Basser as an independent non-executive director, effective from 20 February 2023.
Dr Basser is a medical oncologist and former corporate executive with over 30 years of international medical and biopharmaceutical experience, including 21 years at CSL.
Dr Basser has substantial expertise in international drug and vaccine development, having held multiple senior executive roles whilst at CSL, including Senior Vice President (SVP) of Research and Development at CSL Seqirus; Chief Medical Officer at CSL Limited / CSL Behring; and SVP of Global Clinical Research and Development at CSL Behring / CSL Limited.
Read More